The Korean journal of internal medicine

  • 제33권2호
  • /
  • Pages.347-355
  • /
  • 2018
  • /
  • 1226-3303(pISSN)
  • /
  • 2005-6648(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

Compound K attenuates glucose intolerance and hepatic steatosis through AMPK-dependent pathways in type 2 diabetic OLETF rats

  • Hwang, Yoo-Cheol (Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine) ;
  • Oh, Da-Hee (Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine) ;
  • Choi, Moon Chan (Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine) ;
  • Lee, Sang Yeoul (Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine) ;
  • Ahn, Kyu-Jeong (Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine) ;
  • Chung, Ho-Yeon (Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine) ;
  • Lim, Sung-Jig (Department of Pathology, Kyung Hee University School of Medicine) ;
  • Chung, Sung Hyun (Department of Pharmacology and Clinical Pharmacy Laboratory, Kyung Hee University College of Pharmacy) ;
  • Jeong, In-Kyung (Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine)
  • 투고 : 2015.07.09
  • 심사 : 2015.08.23
  • 발행 : 2018.03.01
⟨ 이전 논문 다음 논문 ⟩

초록

Background/Aims: Non-alcoholic fatty liver disease is associated with insulin resistance. Compound K (CK) is the final metabolite of panaxadiol ginsenosides that have been shown to exert antidiabetic effects. However, the molecular mechanism of the antidiabetic effects in the liver have not been elucidated; further, whether CK has beneficial effects in hepatosteatosis remains unclear. Therefore, we evaluated the effect of CK on hepatosteatosis as well as its mechanism in high-fat diet (HFD)-fed type 2 diabetic Otsuka Long-Evans Tokushima Fatty (OLETF) rats. Methods: Twenty-four-week-old male OLETF rats were assigned to four groups: control (saline), CK 10 mg/kg, CK 25 mg/kg, or metformin 300 mg/kg (positive control); all treatments were administered orally for 12 weeks. Results: Fasting glucose levels of the CK25 group were significantly lower than those of the control group during the 12 weeks. The results of the oral glucose tolerance test showed that both the glucose concentration after glucose loading and the fasting insulin levels of the CK25 group were significantly lower than those of the control. Hepatosteatosis was significantly improved by CK25. CK25 and metformin significantly increased the phosphorylation of hepatic adenosine monophosphate-activated protein kinase (AMPK). CK25 significantly inhibited the expression of sterol regulatory element-binding protein-1c and fatty acid synthase, while upregulating that of peroxisome proliferator-activated receptor-${\alpha}$ and carnitine palmitoyltransferase-1. Conclusions: CK improved glucose intolerance and hepatosteatosis in HFD-fed OLETF rats through AMPK activation, which has dual mode of action that involves decreasing the synthesis of fatty acids and increasing fatty acid oxidation.

키워드

과제정보

연구 과제 주관 기관 : Kyung Hee University

참고문헌

  1. Bloom SR, Kuhajda FP, Laher I, et al. The obesity epidemic: pharmacological challenges. Mol Interv 2008;8:82-98. https://doi.org/10.1124/mi.8.2.6
  2. Wieckowska A, Feldstein AE. Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive. Semin Liver Dis 2008;28:386-395. https://doi.org/10.1055/s-0028-1091983
  3. Stein LL, Dong MH, Loomba R. Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: current status. Adv Ther 2009;26:893-907. https://doi.org/10.1007/s12325-009-0072-z
  4. Ben Djoudi Ouadda A, Levy E, Ziv E, et al. Increased hepatic lipogenesis in insulin resistance and type 2 diabetes is associated with AMPK signalling pathway up-regulation in Psammomys obesus. Biosci Rep 2009;29:283-292. https://doi.org/10.1042/BSR20080141
  5. Osler ME, Zierath JR. Adenosine 5'-monophosphate-activated protein kinase regulation of fatty acid oxidation in skeletal muscle. Endocrinology 2008;149:935-941. https://doi.org/10.1210/en.2007-1441
  6. Lee SJ, Ko WG, Kim JH, Sung JH, Moon CK, Lee BH. Induction of apoptosis by a novel intestinal metabolite of ginseng saponin via cytochrome c-mediated activation of caspase-3 protease. Biochem Pharmacol 2000;60:677-685. https://doi.org/10.1016/S0006-2952(00)00362-2
  7. Yoon SH, Han EJ, Sung JH, Chung SH. Anti-diabetic effects of compound K versus metformin versus compound K-metformin combination therapy in diabetic db/ db mice. Biol Pharm Bull 2007;30:2196-2200. https://doi.org/10.1248/bpb.30.2196
  8. Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander- Tetri BA; NASH Clinical Research Network (CRN). Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 2011;53:810-820. https://doi.org/10.1002/hep.24127
  9. Adams LA, Zein CO, Angulo P, Lindor KD. A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol 2004;99:2365-2368. https://doi.org/10.1111/j.1572-0241.2004.40064.x
  10. Harrison SA, Fincke C, Helinski D, Torgerson S, Hayashi P. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Aliment Pharmacol Ther 2004;20:623-628. https://doi.org/10.1111/j.1365-2036.2004.02153.x
  11. Lindor KD, Kowdley KV, Heathcote EJ, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004;39:770-778. https://doi.org/10.1002/hep.20092
  12. Bugianesi E, Gentilcore E, Manini R, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005;100:1082-1090. https://doi.org/10.1111/j.1572-0241.2005.41583.x
  13. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297-2307. https://doi.org/10.1056/NEJMoa060326
  14. Ota T, Takamura T, Kurita S, et al. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. Gastroenterology 2007;132:282-293. https://doi.org/10.1053/j.gastro.2006.10.014
  15. Kita Y, Takamura T, Misu H, et al. Metformin prevents and reverses inflammation in a non-diabetic mouse model of nonalcoholic steatohepatitis. PLoS One 2012;7:e43056. https://doi.org/10.1371/journal.pone.0043056
  16. Lee J, Hong SW, Rhee EJ, Lee WY. GLP-1 receptor agonist and non-alcoholic fatty liver disease. Diabetes Metab J 2012;36:262-267. https://doi.org/10.4093/dmj.2012.36.4.262
  17. Park KG, Min AK, Koh EH, et al. Alpha-lipoic acid decreases hepatic lipogenesis through adenosine monophosphate- activated protein kinase (AMPK)-dependent and AMPK-independent pathways. Hepatology 2008;48:1477-1486. https://doi.org/10.1002/hep.22496
  18. Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003;98:2485-2490. https://doi.org/10.1111/j.1572-0241.2003.08699.x
  19. Han GC, Ko SK, Sung JH, Chung SH. Compound K enhances insulin secretion with beneficial metabolic effects in db/db mice. J Agric Food Chem 2007;55:10641-10648. https://doi.org/10.1021/jf0722598
  20. Kim DY, Yuan HD, Chung IK, Chung SH. Compound K, intestinal metabolite of ginsenoside, attenuates hepatic lipid accumulation via AMPK activation in human hepatoma cells. J Agric Food Chem 2009;57:1532-1537. https://doi.org/10.1021/jf802867b
  21. Kawano K, Hirashima T, Mori S, Natori T. OLETF (Otsuka Long-Evans Tokushima Fatty) rat: a new NIDDM rat strain. Diabetes Res Clin Pract 1994;24 Suppl:S317-S320. https://doi.org/10.1016/0168-8227(94)90269-0
  22. Steinberg GR, Kemp BE. AMPK in health and disease. Physiol Rev 2009;89:1025-1078. https://doi.org/10.1152/physrev.00011.2008
  23. Viollet B, Lantier L, Devin-Leclerc J, et al. Targeting the AMPK pathway for the treatment of type 2 diabetes. Front Biosci (Landmark Ed) 2009;14:3380-3400.
  24. Shimano H. Sterol regulatory element-binding protein-1 as a dominant transcription factor for gene regulation of lipogenic enzymes in the liver. Trends Cardiovasc Med 2000;10:275-278. https://doi.org/10.1016/S1050-1738(00)00079-7
  25. Shimano H, Horton JD, Shimomura I, Hammer RE, Brown MS, Goldstein JL. Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells. J Clin Invest 1997;99:846-854. https://doi.org/10.1172/JCI119248
  26. Clarke SD. Regulation of fatty acid synthase gene expression: an approach for reducing fat accumulation. J Anim Sci 1993;71:1957-1965. https://doi.org/10.2527/1993.7171957x
  27. Lee SK, Lee JO, Kim JH, et al. Coenzyme Q10 increases the fatty acid oxidation through AMPK-mediated $PPAR{\alpha}$induction in 3T3-L1 preadipocytes. Cell Signal 2012;24:2329-2336. https://doi.org/10.1016/j.cellsig.2012.07.022
  28. Rao MS, Reddy JK. Peroxisomal beta-oxidation and steatohepatitis. Semin Liver Dis 2001;21:43-55. https://doi.org/10.1055/s-2001-12928
  29. Foster DW. The role of the carnitine system in human metabolism. Ann N Y Acad Sci 2004;1033:1-16. https://doi.org/10.1196/annals.1320.001

피인용 문헌

  1. Improving hepatic mitochondrial biogenesis as a postulated mechanism for the antidiabetic effect ofSpirulina platensisin comparison with metformin vol.44, pp.4, 2018, https://doi.org/10.1139/apnm-2018-0354
  2. Effects of compound K, a metabolite of ginsenosides, on memory and cognitive dysfunction in db/db mice involve the inhibition of ER stress and the NLRP3 inflammasome pathway vol.11, pp.5, 2018, https://doi.org/10.1039/c9fo02602a
  3. Lactobacillus fermentum KP-3-fermented ginseng ameliorates alcohol-induced liver disease in C57BL/6N mice through the AMPK and MAPK pathways vol.11, pp.11, 2018, https://doi.org/10.1039/d0fo02396e
  4. Ginsenoside Compound K Promotes Intestinal Peristalsis and the Pharmacokinetic of Metabolite 20(S)-Protopanaxadiol in Relation to Diarrhea vol.2021, pp.None, 2018, https://doi.org/10.1155/2021/5521899
  5. Ginsenosides Improve Nonalcoholic Fatty Liver Disease via Integrated Regulation of Gut Microbiota, Inflammation and Energy Homeostasis vol.12, pp.None, 2021, https://doi.org/10.3389/fphar.2021.622841
  6. Ginsenoside F2 Suppresses Adipogenesis in 3T3-L1 Cells and Obesity in Mice via the AMPK Pathway vol.69, pp.32, 2018, https://doi.org/10.1021/acs.jafc.1c03420
  7. Allopurinol ameliorates high fructose diet induced hepatic steatosis in diabetic rats through modulation of lipid metabolism, inflammation, and ER stress pathway vol.11, pp.1, 2021, https://doi.org/10.1038/s41598-021-88872-7
  8. Hypoglycemic and Hypolipidemic Effects of Malonyl Ginsenosides from American Ginseng (Panax quinquefolius L.) on Type 2 Diabetic Mice vol.6, pp.49, 2018, https://doi.org/10.1021/acsomega.1c04656
  9. AMPK signaling in diabetes mellitus, insulin resistance and diabetic complications: A pre-clinical and clinical investigation vol.146, pp.None, 2018, https://doi.org/10.1016/j.biopha.2021.112563